Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
12 sept. 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
27 août 2024 16h05 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
21 août 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
14 août 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
09 août 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
09 août 2024 08h00 HE
|
Monopar Therapeutics Inc.
Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024 ...
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
09 juil. 2024 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
25 juin 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar and NorthStar Amend & Extend Collaboration
11 juin 2024 07h30 HE
|
Monopar Therapeutics Inc.
Highlights: Builds on Companies’ respective core strengthsAligns intellectual property rightsEstablishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s...